India, Feb. 6 -- From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.
The company we are referring to is Monopar Therapeutics Inc. (MNPR), developing ALXN1840 for Wilson Disease and MNPR-101 as a novel radiopharmaceutical targeting uPAR (urokinase-type plasminogen activator receptor), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
Monopar was featured on our site on Sep.26, 2024, when it was trading at $5.44. The turning point that altered the trajectory of its stock price was the company's agreement with Alexion, AstraZeneca Rare Disease for ALXN-1840, signed on Octobe...